Mycobiology

The Korean Society of Mycology (한국균학회)
권호 표지
DOI QR코드

DOI QR Code

Mycelial Extract of Phellinus linteus Induces Cell Death in A549 Lung Cancer Cells and Elevation of Nitric Oxide in Raw 264.7 Macrophage Cells

  • Lee, Jong-Jin (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.) ;
  • Kwon, Ho-Kyun (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.) ;
  • Lee, Dong-Soo (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.) ;
  • Lee, Seung-Woo (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.) ;
  • Lee, Kye-Kwan (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.) ;
  • Kim, Kyu-Joong (Department of Biology, Kangnung National University) ;
  • Kim, Jong-Lae (Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd.)
  • Published : 2006.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

In the present study, in order to investigate the anti-proliferative phenomenon of PLME, the effects of mycelial extract of Phellinus linteus (PLME) on the growth of human lung carcinoma cell line A549 was examined. We studied on the effects of PLME on the release of nitric oxide (NO) in mouse macrophage Raw 264.7 cells. Treatment of PLME to A549 cells resulted in the growth inhibition, morphological change and induction of apoptotic cell death in a dose-dependent manner as measured by MTT assay. We found that PLME stimulated a dose-dependent increase in NO production. These findings suggest that PLME enhances the anti-tumoral activity of macrophage and may be a potential therapeutic agent for the control of human lung carcinoma cells.

Keywords

References

  1. Bededovsky, H. O. and Del Rey, A. 1996. Immuno-neuro-endocrineinteractions: facts and hypotheses. Endocrine Review 17: 64-102 https://doi.org/10.1210/edrv-17-1-64
  2. Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M. and Johnson, D. 2000. Comparisons of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18: 623-631 https://doi.org/10.1200/JCO.2000.18.3.623
  3. Cardenal, F., Lopez-Cabrerizo, M. P., Anton, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., Garcia, M., Lianes, P., Montalar, J., Vadell, C., Gonzalez-Larriba, J. L., Nguyen, B., Artal, A. and Rosell, R. 1999. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cenacer. J. Clin. Oncol. 17: 12-18 https://doi.org/10.1200/JCO.1999.17.1.12
  4. Collins, L., Zhu, T., Guo, J., Xiao, Z. J. and Chen, C. Y. 2006. Phellinus linteus sensitizes apoptosis induced by doxorubicin in prostate cancer. British. J. Cancer. 95: 282-288 https://doi.org/10.1038/sj.bjc.6603277
  5. Duan, W., Yu, Y. and Zhang, L. 2005. Antiatherogenic effects of Phyllantus Emblica associated with Corilagin and its Analogue. Yakugaku Zasshi 5: 587-591
  6. Duerksen-Hughes, P. J., Day, D., Laster, S. M., Zachariades, N. A., Aquino, L. and Gooding, L. R. 1992. Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40transformed cells by activated macrophages. J. Immunol. 149: 2114-2122
  7. Eisenberg, D. M., Davis, R. B., Ettner, S. L., Wilkey, S., Van, Rompay. M. and Kessler, R. G 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. J. Am. Med. Assoc. 280: 1569-1575 https://doi.org/10.1001/jama.280.18.1569
  8. Fidler, I. J. and Kleinerman, E. S. 1993. Therapy of cancer metastasis by systemic activation of macrophages; from bench to the clinic. Res. Immunol. 144: 274-276 https://doi.org/10.1016/0923-2494(93)80106-9
  9. Flick, D. A. and Gifford, G E. 1984. Comparison of in vitro cell cytotoxicity assays for tumor necrosis factor. J. Immunol. 68: 167-175 https://doi.org/10.1016/0022-1759(84)90147-9
  10. Han, S. B., Lee, C. W., Jeon, Y. J., Hong, N. D., Yoo, I. D., Yang, K. H. and Kim, H. M. 1999. The inhibitory effect of polysaccharide isolated from Phellinus linteus on tumor growth and metastasis. Immunopharm. 41: 157-164 https://doi.org/10.1016/S0162-3109(98)00063-0
  11. Han, S. B., Lee, C. W., Jeon, Y. J., Hong, N. D., Yoo, I. D., Yang, K. H. and Kim, H. M. 1999. The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 41: 157-164 https://doi.org/10.1016/S0162-3109(98)00063-0
  12. Klostergaard, J. 1993. Macrophages tumoricial mechanism. Res. Immunol. 87: 581-586
  13. Lowenstein, C. J., Dinerman, J. L. and Snyder, S. H. 1994. Nitric oxide: A physiologic messenger. Annals Int. Medicine 120: 227-237 https://doi.org/10.7326/0003-4819-120-3-199402010-00009
  14. Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H. and Russell, S. W. 1993. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide. J. Biol. Chem. 268: 1908-1913
  15. Moncada, S., Palmer, R. M. and Higgs, E. A. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43: 109-142
  16. Mountain, C. F. 1997. Revisions in the international system for staging lung cancer. Chest 111: 1710-1717 https://doi.org/10.1378/chest.111.6.1710
  17. Poderoso, J. J., Carreras, M. c., Schopfer, F., Lisdero, C. L., Riobo, N. A., Giulivi, C., Boveris, A. D., Boveris, A. and Cadenas, E. 1999. The reaction of nitric oxide with ubiquinol: kinetic properties and biological significance. Free Radical Biol. Medicine 26: 925-935 https://doi.org/10.1016/S0891-5849(98)00277-9
  18. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D. H. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. J. Med. 346: 92-98 https://doi.org/10.1056/NEJMoa011954
  19. Stuehr, D. J. and Nathan, C. F. 1989. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169: 1543-1555 https://doi.org/10.1084/jem.169.5.1543
  20. Van, F. R., Sluiter, W. V. and Dissel, J. T. 1986. Genetic control of monocyte production and macrophage function. In: Steinman, R. M. and North, R. J. (Eds.), Mechanisms of Host Resistance to Infectious Agents, Tumor, and Allografts. Rockeller Universiy, New York. 138
  21. Wasser, S. P. 2002. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl. Microbial. Biotech. 60: 258-274 https://doi.org/10.1007/s00253-002-1076-7

Cited by

  1. vol.37, pp.1, 2009, https://doi.org/10.4489/MYCO.2009.37.1.021
  2. The MSHA strain of Pseudomonas aeruginosa (PA-MSHA) inhibits gastric carcinoma progression by inducing M1 macrophage polarization vol.37, pp.5, 2016, https://doi.org/10.1007/s13277-015-4451-6